Maladie de Chagas : Questions médicales fréquentes
Nom anglais: Chagas Disease
Descriptor UI:D014355
Tree Number:C01.920.625
Termes MeSH sélectionnés :
Prostate-Specific Antigen
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Maladie de Chagas : Questions médicales les plus fréquentes",
"headline": "Maladie de Chagas : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Maladie de Chagas : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-25",
"dateModified": "2025-03-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Maladie de Chagas"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies vectorielles",
"url": "https://questionsmedicales.fr/mesh/D000079426",
"about": {
"@type": "MedicalCondition",
"name": "Maladies vectorielles",
"code": {
"@type": "MedicalCode",
"code": "D000079426",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.920"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Maladie de Chagas",
"alternateName": "Chagas Disease",
"code": {
"@type": "MedicalCode",
"code": "D014355",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Israel Molina",
"url": "https://questionsmedicales.fr/author/Israel%20Molina",
"affiliation": {
"@type": "Organization",
"name": "Tropical Medicine Unit, Department of Infectious Diseases, Vall d'Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain; Instituto René Rachou-FIOCRUZ Minas, Chagas Disease Research Group, Belo Horizonte, MG, Brazil."
}
},
{
"@type": "Person",
"name": "Eva H Clark",
"url": "https://questionsmedicales.fr/author/Eva%20H%20Clark",
"affiliation": {
"@type": "Organization",
"name": "Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA."
}
},
{
"@type": "Person",
"name": "Caryn Bern",
"url": "https://questionsmedicales.fr/author/Caryn%20Bern",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, California, USA."
}
},
{
"@type": "Person",
"name": "Carlos A Morillo",
"url": "https://questionsmedicales.fr/author/Carlos%20A%20Morillo",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiology, Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Foothills Medical Centre, Room C823, 1403 29th Street Northwest, Calgary, Alberta T2N 2T9, Canada. Electronic address: carlos.morillo@ucalgary.ca."
}
},
{
"@type": "Person",
"name": "Susan P Montgomery",
"url": "https://questionsmedicales.fr/author/Susan%20P%20Montgomery",
"affiliation": {
"@type": "Organization",
"name": "Parasitic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia (S.P.M.)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prostate-Specific Membrane Antigen PET/Computed Tomography: Pearls and Pitfalls.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37973240",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.rcl.2023.07.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Positive Prostate-specific Membrane Antigen Findings: How To Interpret Them.",
"datePublished": "2022-11-22",
"url": "https://questionsmedicales.fr/article/36428201",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.euo.2022.10.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sandwich-Type Electrochemical Aptasensor with Supramolecular Architecture for Prostate-Specific Antigen.",
"datePublished": "2024-10-05",
"url": "https://questionsmedicales.fr/article/39407641",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules29194714"
}
},
{
"@type": "ScholarlyArticle",
"name": "Chitosan/luminol/AgNPs nanocomposite for electrochemiluminescent determination of prostate-specific antigen.",
"datePublished": "2023-02-14",
"url": "https://questionsmedicales.fr/article/36786882",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00604-023-05680-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate-specific antigen level association with COVID-19 infection and vaccination.",
"datePublished": "2023-05-05",
"url": "https://questionsmedicales.fr/article/37270370",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2023.05.001"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies vectorielles",
"item": "https://questionsmedicales.fr/mesh/D000079426"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maladie de Chagas",
"item": "https://questionsmedicales.fr/mesh/D014355"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Maladie de Chagas - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Maladie de Chagas",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Maladie de Chagas",
"description": "Comment diagnostique-t-on la maladie de Chagas ?\nQuels examens sont utilisés pour le diagnostic ?\nPeut-on diagnostiquer la maladie par biopsie ?\nQuels sont les signes cliniques au diagnostic ?\nLa maladie de Chagas est-elle toujours symptomatique ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Prostate-Specific+Antigen&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Maladie de Chagas",
"description": "Quels sont les symptômes aigus de la maladie de Chagas ?\nQuels symptômes chroniques peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment se manifeste l'œdème de l'œil ?\nLes symptômes varient-ils selon les régions ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Prostate-Specific+Antigen&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Maladie de Chagas",
"description": "Comment prévenir la maladie de Chagas ?\nLes moustiquaires sont-elles efficaces ?\nL'éducation sanitaire joue-t-elle un rôle ?\nLes tests de dépistage sont-ils importants ?\nPeut-on prévenir la transmission par voie orale ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Prostate-Specific+Antigen&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Maladie de Chagas",
"description": "Quel est le traitement principal de la maladie de Chagas ?\nLe traitement est-il efficace à tous les stades ?\nY a-t-il des effets secondaires au traitement ?\nDes traitements alternatifs existent-ils ?\nLe traitement prévient-il les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Prostate-Specific+Antigen&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Maladie de Chagas",
"description": "Quelles sont les complications cardiaques possibles ?\nLa maladie peut-elle affecter le système digestif ?\nY a-t-il des risques de décès liés à la maladie ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Prostate-Specific+Antigen&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Maladie de Chagas",
"description": "Quels sont les principaux facteurs de risque ?\nLes voyages dans certaines régions augmentent-ils le risque ?\nLes conditions de vie influencent-elles le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes personnes immunodéprimées sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D014355?mesh_terms=Prostate-Specific+Antigen&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la maladie de Chagas ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sérologiques pour détecter les anticorps anti-T. cruzi."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme l'ELISA, l'immunofluorescence et la PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer la maladie par biopsie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie de tissu peut révéler la présence du parasite dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques au diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes peuvent inclure des œdèmes, des éruptions cutanées et des symptômes cardiaques."
}
},
{
"@type": "Question",
"name": "La maladie de Chagas est-elle toujours symptomatique ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle peut être asymptomatique pendant des années avant d'entraîner des complications."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes aigus de la maladie de Chagas ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent fièvre, fatigue, et gonflement au site de la piqûre."
}
},
{
"@type": "Question",
"name": "Quels symptômes chroniques peuvent apparaître ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes chroniques incluent des problèmes cardiaques et digestifs, comme l'arythmie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées et des lésions peuvent se développer, surtout au stade aigu."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'œdème de l'œil ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'œdème de l'œil, ou signe de Romaña, se manifeste par un gonflement autour de l'œil."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les régions ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la souche du parasite et de l'hôte."
}
},
{
"@type": "Question",
"name": "Comment prévenir la maladie de Chagas ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'amélioration des conditions de logement et l'utilisation d'insecticides."
}
},
{
"@type": "Question",
"name": "Les moustiquaires sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les moustiquaires peuvent réduire le contact avec les insectes vecteurs de la maladie."
}
},
{
"@type": "Question",
"name": "L'éducation sanitaire joue-t-elle un rôle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques et les méthodes de prévention est cruciale pour réduire l'incidence."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage des donneurs de sang et des femmes enceintes est essentiel pour prévenir la transmission."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la transmission par voie orale ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter la consommation d'aliments contaminés peut prévenir la transmission orale de la maladie."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal de la maladie de Chagas ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'utilisation de médicaments antiparasitaires comme le benznidazole."
}
},
{
"@type": "Question",
"name": "Le traitement est-il efficace à tous les stades ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est plus efficace au stade aigu; son efficacité diminue au stade chronique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires au traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des éruptions cutanées et des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Des traitements alternatifs existent-ils ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements alternatifs sont en cours d'étude, mais le benznidazole reste le standard."
}
},
{
"@type": "Question",
"name": "Le traitement prévient-il les complications ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce peut réduire le risque de complications à long terme, comme les problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications cardiaques possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications cardiaques incluent l'insuffisance cardiaque, les arythmies et la cardiomyopathie."
}
},
{
"@type": "Question",
"name": "La maladie peut-elle affecter le système digestif ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications digestives comme l'agrandissement de l'œsophage ou du côlon peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de décès liés à la maladie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications graves peuvent entraîner la mort, surtout si non traitées."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais beaucoup sont irréversibles sans traitement précoce."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent gravement affecter la qualité de vie, limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la pauvreté, le manque d'accès à des logements sains et l'exposition aux insectes vecteurs."
}
},
{
"@type": "Question",
"name": "Les voyages dans certaines régions augmentent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones endémiques augmente le risque d'exposition au parasite."
}
},
{
"@type": "Question",
"name": "Les conditions de vie influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, vivre dans des habitations en terre ou en bois augmente le risque d'infestation par les triatomes."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des antécédents familiaux de la maladie peut augmenter le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées peuvent être plus susceptibles de développer des formes graves de la maladie."
}
}
]
}
]
}
Prostate-specific membrane antigen PET (PSMA-PET) has emerged as a powerful imaging tool for prostate cancer primary staging, biochemical recurrence, and advanced disease assessment. This article offe...
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is more accurate than conventional imaging for primary staging of high-risk prostate cancer and loca...
A novel sandwich-type electrochemical aptasensor based on supramolecularly immobilized affinity bioreceptor was prepared via host-guest interactions. This method utilizes an adamantane-modified, targe...
A green, environmentally friendly protocol was developed for ultrasensitive and highly specific recognition of prostate-specific antigen (PSA) based on the ECL effect of luminol supported by chitosan-...
The associations among SARS-CoV-2 infection, vaccination and total serum prostate serum antigen (PSA) levels in men undergoing screening for prostate cancer are unknown....
A retrospective analysis of data from a large health maintenance organization. Records of individuals aged 50 to 75 years with two serum PSA tests taken between March 2018 and November 2021 were inclu...
The study and control groups included 6,733 (29%) and 16 286 (71%) individuals, respectively. Although the median time between PSA tests was shorter in the study vs. the control group (440 vs. 469 day...
SARS-CoV-2 infection and vaccinations are associated with a slight increase in PSA, with the third anti-COVID vaccine dose having a more prominent impact, but its clinical significance is unknown yet....
An efficient strategy for the establishment of ratiometric antifouling electrochemical biosensors was proposed based on the designed functional peptides and synthesized graphene oxide-nile blue A (GO-...
The relationship between prostate-specific antigen (PSA) and prostate cancer (PCa) grade was traditionally thought to be linear but recent reports suggest this is not true in high-grade cancers. We ai...
Retrospective cohort study using the National Prostate Cancer Audit database in England of men treated with external beam radiotherapy (EBRT), EBRT and brachytherapy boost (EBRT + BT), radical prostat...
102,089 men were included, of whom 71,138 had low/intermediate-grade and 22,425 had high-grade PCa. In high-grade, 4-year PCSM was higher with PSA ≤5 than PSA 5.1-10 for men treated with EBRT (hazard ...
The low-PSA/high-grade combination in M0 PCa treated with EBRT has a higher PCSM than those with high-grade and intermediate PSA levels. In high-grade disease, the PSA association was non-linear; by c...
This study analyzes the value of PSA kinetics, PSA speed (vPSA), and PSA doubling time (PSAdt), in patients with low-risk prostate cancer who are in an active surveillance (AS) program....
An observational, retrospective, and longitudinal study of a sample of 86 patients included in AS program between January 2014 and October 2021 was conducted. A review of their medical records was per...
The mean age was 63.39 years, and the median follow-up was 62.55 months. The mean PSA at diagnosis was 8.27 ng/mL. A median of PSAdt of 62.55 months and 1.3 ng/mL/year for vPSA was obtained. 35 patien...
PSA kinetics is a parameter to take into account when making decisions to keep patients in an AS program....
Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and ...
Limited data exist on trends in PSA screening in men with a family history of prostate cancer. The aims of our study were to (1) study age-stratified temporal trends in PSA screening from 2000-2018 fo...
We identified men aged ≥40 years without a prior history of prostate cancer using data from National Health Interview Survey 2000-2018 who self-reported PSA testing in the last 12 months. Age-stratifi...
PSA screening increased for men with a family history of prostate cancer between National Health Interview Survey 2000 (28.9%) and 2005 (41.9%), with stable rates for the following years. Black men wi...
Data from a nationally representative study of U.S. men indicated that the annual PSA screening rates for men with a family history of prostate cancer was higher than reported for the overall male pop...